CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Science magazine has named the company the world’s number one employer in its annual survey of the biotech and pharmaceutical industry.
“We are deeply honored to be named the top employer by Science in the very first year we were included in the survey, as we continue to build a top-tier, independent biopharmaceutical company founded on RNAi,” said John Maraganore, Ph.D., Chief Executive Officer, Alnylam Pharmaceuticals. “This recognition is a testament to the efforts of our more than 1,200 employees around the world who work tirelessly every day to advance RNAi therapeutics as a new class of innovative medicines to patients in need and embodies the bold scientific endeavor and pioneering spirit that spurred our founding just over 17 years ago.”
Results were based on 7,658 surveys of people in the industry who rated companies on attributes such as corporate image, leadership and direction, work culture/environment, and academic and intellectual challenge. According to Science, the 2019 global survey results were based on responses from North America (72 percent), Europe (19 percent) and the Asia/Pacific Rim (7 percent).
“Science has long recognized innovative leaders within our industry, and we are thrilled to be ranked at the top of this esteemed list,” said Akshay Vaishnaw, M.D., Ph.D., President, Research & Development, Alnylam Pharmaceuticals. “It’s quite gratifying to have our science and culture recognized as we work hard to discover and develop the next wave of RNAi therapeutics for patients with serious diseases.”
For the complete feature and company rankings, please visit: https://www.sciencemag.org/features/2019/10/top-employers-breakthroughs-impact-purpose.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. Alnylam’s first commercial RNAi therapeutic is ONPATTRO® (patisiran), approved in the U.S., EU, Canada, Japan, and Switzerland. Alnylam has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1,200 people worldwide and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.